KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer.

RAS genes (HRAS, KRAS, and NRAS) comprise the most frequently mutated oncogene family in human cancer. With the highest RAS mutation frequencies seen with the top three causes of cancer deaths in the United States (lung, colorectal, and pancreatic cancer), the development of anti-RAS therapies is a major priority for cancer research. Despite more than three decades of intense effort, no effective RAS inhibitors have yet to reach the cancer patient. With bitter lessons learned from past failures and with new ideas and strategies, there is renewed hope that undruggable RAS may finally be conquered. With the KRAS isoform mutated in 84% of all RAS-mutant cancers, we focus on KRAS. With a near 100% KRAS mutation frequency, pancreatic ductal adenocarcinoma (PDAC) is considered the most RAS-addicted of all cancers. We review the role of KRAS as a driver and therapeutic target in PDAC.

[1]  Michael R. Green,et al.  Gene Expression , 1993, Progress in Gene Expression.

[2]  Kevan M. Shokat,et al.  K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions , 2013, Nature.

[3]  Patricia Greninger,et al.  A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. , 2009, Cancer cell.

[4]  A. Jubb,et al.  p21-Activated kinase 1 is required for efficient tumor formation and progression in a Ras-mediated skin cancer model. , 2012, Cancer research.

[5]  P. Edwards,et al.  Amplification of the Driving Oncogene, KRAS or BRAF, Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells , 2011, Science Signaling.

[6]  Laura M. Heiser,et al.  A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma. , 2012, Cancer discovery.

[7]  O. Sansom,et al.  GEMMs as preclinical models for testing pancreatic cancer therapies , 2015, Disease Models & Mechanisms.

[8]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[9]  John M. Lambert,et al.  Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism , 2002, Nature Cell Biology.

[10]  M. Kanda,et al.  Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. , 2012, Gastroenterology.

[11]  Ben S. Wittner,et al.  Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.

[12]  B. Spencer‐Dene,et al.  Requirement for Interaction of PI3-Kinase p110α with RAS in Lung Tumor Maintenance , 2013, Cancer cell.

[13]  C. Der,et al.  Drugging RAS: Know the enemy , 2017, Science.

[14]  S. Fesik,et al.  Drugging the undruggable RAS: Mission Possible? , 2014, Nature Reviews Drug Discovery.

[15]  C. Der,et al.  Targeting RAS-mutant cancers: is ERK the key? , 2015, Trends in cancer.

[16]  Toshio Shimizu,et al.  A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors , 2015, Investigational New Drugs.

[17]  D. Morrison,et al.  MAP kinase pathways. , 2012, Cold Spring Harbor perspectives in biology.

[18]  E. Petricoin,et al.  Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression. , 2016, Cancer cell.

[19]  C. Galbán,et al.  Metastatic Pancreatic Cancer Is Dependent on Oncogenic Kras in Mice , 2012, PloS one.

[20]  C. Der,et al.  The RalB Small GTPase Mediates Formation of Invadopodia through a GTPase-Activating Protein-Independent Function of the RalBP1/RLIP76 Effector , 2012, Molecular and Cellular Biology.

[21]  E. Assenat,et al.  KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma , 2016, Clinical and Translational Gastroenterology.

[22]  Shan Jiang,et al.  Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer , 2014, Cell.

[23]  T. Schoeb,et al.  Inactivation of Smad4 accelerates Kras(G12D)-mediated pancreatic neoplasia. , 2007, Cancer research.

[24]  P. Hipskind,et al.  Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells. , 2015, Journal of medicinal chemistry.

[25]  E. Petricoin,et al.  Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. , 2003, Cancer cell.

[26]  D. Esposito,et al.  Dragging ras back in the ring. , 2014, Cancer cell.

[27]  H. Rui,et al.  Dormant cancer cells contribute to residual disease in a model of reversible pancreatic cancer. , 2013, Cancer research.

[28]  Gerald C. Chu,et al.  Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism , 2012, Cell.

[29]  K. Lim,et al.  Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance. , 2005, Cancer cell.

[30]  C. Der,et al.  RAS isoforms and mutations in cancer at a glance , 2016, Journal of Cell Science.

[31]  S. Adam,et al.  Divergent Roles for RalA and RalB in Malignant Growth of Human Pancreatic Carcinoma Cells , 2006, Current Biology.

[32]  P. Poulikakos,et al.  Targeting RAS–ERK signalling in cancer: promises and challenges , 2014, Nature Reviews Drug Discovery.

[33]  D. Morrison,et al.  The importance of Raf dimerization in cell signaling , 2013, Small GTPases.

[34]  D. Tuveson,et al.  C-Raf is required for the initiation of lung cancer by K-Ras(G12D). , 2011, Cancer discovery.

[35]  G. Stamp,et al.  RalGDS is required for tumor formation in a model of skin carcinogenesis. , 2005, Cancer cell.

[36]  A. Tolcher,et al.  A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  Joseph Rosenbluh,et al.  KRAS and YAP1 Converge to Regulate EMT and Tumor Survival , 2014, Cell.

[38]  H. Hirsch,et al.  Evaluating TBK1 as a Therapeutic Target in Cancers with Activated IRF3 , 2014, Molecular Cancer Research.

[39]  M. Belvin,et al.  RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth , 2010, Nature.

[40]  R. DePinho,et al.  Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. , 2003, Genes & development.

[41]  Xiwen Ma,et al.  Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers. , 2015, Cancer cell.

[42]  P. Murawa,et al.  Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Mari Mino-Kenudson,et al.  EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. , 2012, Cancer discovery.

[44]  James Tsai,et al.  RAF inhibitors that evade paradoxical MAPK pathway activation , 2015, Nature.

[45]  Michio Shimizu,et al.  An Illustrated Consensus on the Classification of Pancreatic Intraepithelial Neoplasia and Intraductal Papillary Mucinous Neoplasms , 2004, The American journal of surgical pathology.

[46]  V. Velculescu,et al.  Genetic Basis of Pancreas Cancer Development and Progression: Insights from Whole-Exome and Whole-Genome Sequencing , 2012, Clinical Cancer Research.

[47]  P. Mazur,et al.  Early requirement of Rac1 in a mouse model of pancreatic cancer. , 2011, Gastroenterology.

[48]  J. Reis-Filho,et al.  Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF , 2010, Cell.

[49]  M. Barbacid,et al.  c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. , 2011, Cancer cell.

[50]  Rony Seger,et al.  The MEK/ERK cascade: from signaling specificity to diverse functions. , 2007, Biochimica et biophysica acta.

[51]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[52]  John C. Hunter,et al.  Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations , 2015, Molecular Cancer Research.

[53]  C. Der,et al.  Ral small GTPase signaling and oncogenesis: More than just 15minutes of fame. , 2014, Biochimica et biophysica acta.

[54]  Kaitlyn Le,et al.  Inhibition of mutant BRAF splice variant signaling by next‐generation, selective RAF inhibitors , 2014, Pigment cell & melanoma research.

[55]  D. Morrison,et al.  Integrating signals from RTKs to ERK/MAPK , 2007, Oncogene.

[56]  D. Aust,et al.  Precursor Lesions for Sporadic Pancreatic Cancer: PanIN, IPMN, and MCN , 2014, BioMed research international.

[57]  S. H. Young,et al.  Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2 , 2015, Molecular Cancer Therapeutics.

[58]  A. Sivachenko,et al.  A Landscape of Driver Mutations in Melanoma , 2012, Cell.

[59]  E. Fishman,et al.  Recent progress in pancreatic cancer , 2013, CA: a cancer journal for clinicians.

[60]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[61]  Prasenjit Dey,et al.  Genetics and biology of pancreatic ductal adenocarcinoma , 2006, Genes & development.

[62]  Michael A. Choti,et al.  Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets , 2015, Nature Communications.

[63]  D. Bar-Sagi,et al.  Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response. , 2014, Cancer cell.

[64]  C. Der,et al.  Aberrant Overexpression of the Rgl2 Ral Small GTPase-specific Guanine Nucleotide Exchange Factor Promotes Pancreatic Cancer Growth through Ral-dependent and Ral-independent Mechanisms* , 2010, The Journal of Biological Chemistry.

[65]  Mitsuhiko Ikura,et al.  NMR-based functional profiling of RASopathies and oncogenic RAS mutations , 2013, Proceedings of the National Academy of Sciences.

[66]  R. Hruban,et al.  Disruption of p16 and Activation of Kras in Pancreas Increase Ductal Adenocarcinoma Formation and Metastasis in vivo , 2011, Oncotarget.

[67]  G. Stamp,et al.  Binding of Ras to Phosphoinositide 3-Kinase p110α Is Required for Ras- Driven Tumorigenesis in Mice , 2007, Cell.

[68]  G. Evan,et al.  Modelling Myc inhibition as a cancer therapy , 2008, Nature.

[69]  K. Lim,et al.  Tumour maintenance is mediated by eNOS , 2008, Nature.

[70]  J. Cherfils,et al.  Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? , 2010, Nature Reviews Cancer.

[71]  C. Der,et al.  Ras history , 2010, Small GTPases.

[72]  D. MacAlpine,et al.  Rare Codons Regulate KRas Oncogenesis , 2013, Current Biology.

[73]  Carla Mattos,et al.  A comprehensive survey of Ras mutations in cancer. , 2012, Cancer research.

[74]  Lincoln D. Stein,et al.  Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes , 2012, Nature.

[75]  G. Stamp,et al.  Genetic Deletion of RALA and RALB Small GTPases Reveals Redundant Functions in Development and Tumorigenesis , 2012, Current Biology.

[76]  R. Arceci.  RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors , 2012 .

[77]  R. Bernards,et al.  Stable suppression of tumorigenicity by virus-mediated RNA interference. , 2002, Cancer cell.

[78]  K. Flaherty,et al.  RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. , 2012, The New England journal of medicine.

[79]  D. Bar-Sagi,et al.  Induction of membrane ruffling and fluid-phase pinocytosis in quiescent fibroblasts by ras proteins. , 1986, Science.

[80]  R. Hruban,et al.  Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. , 2005, Cancer cell.

[81]  J. Kench,et al.  Whole genomes redefine the mutational landscape of pancreatic cancer , 2015, Nature.

[82]  M. Shipitsin,et al.  Activation of RalA is critical for Ras-induced tumorigenesis of human cells. , 2005, Cancer cell.

[83]  C. Der,et al.  Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation , 1995, Molecular and cellular biology.

[84]  C. Galbán,et al.  Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. , 2012, The Journal of clinical investigation.

[85]  C. Moskaluk,et al.  Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. , 1997, Cancer research.

[86]  Matthew J. Davis,et al.  Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma , 2012, Nature Genetics.

[87]  Colin J. Daniel,et al.  Oncogenes and Tumor Suppressors Targeting Inhibitors of the Tumor Suppressor PP 2 A for the Treatment of Pancreatic Cancer , 2014 .

[88]  Julian Downward,et al.  RAS Interaction with PI3K: More Than Just Another Effector Pathway. , 2011, Genes & cancer.

[89]  Shih-Hsun Chen,et al.  Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120. , 2016, Cancer discovery.

[90]  Shuxia Zhao,et al.  Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. , 2013, Cancer discovery.

[91]  John G. Collard,et al.  Mice deficient in the Rac activator Tiam1 are resistant to Ras-induced skin tumours , 2002, Nature.

[92]  Taebo Sim,et al.  Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor. , 2014, Angewandte Chemie.

[93]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[94]  G. Stamp,et al.  RAS and RHO Families of GTPases Directly Regulate Distinct Phosphoinositide 3-Kinase Isoforms , 2013, Cell.

[95]  K. Olive,et al.  Genetically engineered mouse models of pancreatic cancer. , 2012, Cancer journal.

[96]  R. Sears,et al.  MYC degradation. , 2014, Cold Spring Harbor perspectives in medicine.

[97]  P. Stephens,et al.  Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2. , 2016, Cancer cell.

[98]  R. Scharpf,et al.  Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients , 2015, Nature Communications.

[99]  F. McCormick,et al.  An essential role for Rac in Ras transformation , 1995, Nature.

[100]  Joon-Oh Park,et al.  A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. , 2014, European journal of cancer.

[101]  R. Bjornson,et al.  Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors , 2013, Pigment cell & melanoma research.

[102]  D. MacAlpine,et al.  Rare codons capacitate Kras-driven de novo tumorigenesis. , 2015, The Journal of clinical investigation.

[103]  Nicole M. Baker,et al.  Molecular Pathways: Targeting RAC–p21-Activated Serine–Threonine Kinase Signaling in RAS-Driven Cancers , 2014, Clinical Cancer Research.

[104]  Rebecca L. Siegel Mph,et al.  Cancer statistics, 2016 , 2016 .

[105]  Ralph Weissleder,et al.  Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[106]  D. Shibata,et al.  Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes , 1988, Cell.

[107]  Chao Zhang,et al.  RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF , 2010, Nature.

[108]  R H Hruban,et al.  Progression model for pancreatic cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[109]  R. Rad,et al.  Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. , 2013, Cancer cell.